ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 565 industry peers in the Biotechnology industry. While ORGO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a positive operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.73%, ORGO belongs to the top of the industry, outperforming 90.73% of the companies in the same industry.
ORGO has a better Return On Equity (-6.27%) than 91.98% of its industry peers.
With an excellent Return On Invested Capital value of 2.08%, ORGO belongs to the best of the industry, outperforming 93.40% of the companies in the same industry.
ORGO had an Average Return On Invested Capital over the past 3 years of 6.08%. This is significantly below the industry average of 15.39%.
The last Return On Invested Capital (2.08%) for ORGO is well below the 3 year average (6.08%), which needs to be investigated, but indicates that ORGO had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.73% | ||
| ROE | -6.27% | ||
| ROIC | 2.08% |
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of ORGO has declined.
The Operating Margin of ORGO (2.67%) is better than 93.40% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a Gross Margin of 75.14%. This is amongst the best in the industry. ORGO outperforms 85.20% of its industry peers.
In the last couple of years the Gross Margin of ORGO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.67% | ||
| PM (TTM) | N/A | ||
| GM | 75.14% |
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ORGO has more shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
ORGO has an Altman-Z score of 3.02. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
ORGO has a Altman-Z score of 3.02. This is in the better half of the industry: ORGO outperforms 75.22% of its industry peers.
ORGO has a debt to FCF ratio of 7.74. This is a slightly negative value and a sign of low solvency as ORGO would need 7.74 years to pay back of all of its debts.
ORGO has a better Debt to FCF ratio (7.74) than 93.58% of its industry peers.
ORGO has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a worse Debt to Equity ratio (0.22) than 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 7.74 | ||
| Altman-Z | 3.02 |
ROIC/WACC0.2
WACC10.18%
2.3 Liquidity
A Current Ratio of 2.73 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Current ratio of 2.73. This is in the lower half of the industry: ORGO underperforms 68.09% of its industry peers.
ORGO has a Quick Ratio of 2.42. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.42, ORGO is not doing good in the industry: 70.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.00% over the past year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -30.66% on average per year.
Looking at the last year, ORGO shows a decrease in Revenue. The Revenue has decreased by -3.94% in the last year.
The Revenue has been growing by 17.50% on average over the past years. This is quite good.
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5YN/A
EPS Q2Q%350%
Revenue 1Y (TTM)-3.94%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Sales Q2Q%6.13%
3.2 Future
The Earnings Per Share is expected to grow by 8.44% on average over the next years. This is quite good.
ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-533.5%
EPS Next 2Y-73.78%
EPS Next 3Y8.44%
EPS Next 5YN/A
Revenue Next Year3.27%
Revenue Next 2Y1.66%
Revenue Next 3Y4.23%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ORGO is valuated quite expensively with a Price/Earnings ratio of 35.09.
ORGO's Price/Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 94.83% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.53. ORGO is valued slightly more expensive when compared to this.
The Forward Price/Earnings Ratio is negative for ORGO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.09 | ||
| Fwd PE | N/A |
4.2 Price Multiples
95.37% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
94.65% of the companies in the same industry are more expensive than ORGO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.09 | ||
| EV/EBITDA | 17.33 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.78%
EPS Next 3Y8.44%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGANOGENESIS HOLDINGS INC
NASDAQ:ORGO (11/15/2024, 8:00:01 PM)
3.86
-0.15 (-3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap511.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.09 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.73% | ||
| ROE | -6.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 2.67% | ||
| PM (TTM) | N/A | ||
| GM | 75.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5Y
EPS Q2Q%
EPS Next Y-533.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.94%
Revenue growth 3Y8.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y